Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 10—October 2024
Dispatch
Presumed Transmission of 2 Distinct Monkeypox Virus Variants from Central African Republic to Democratic Republic of the Congo
Suggested citation for this article
Abstract
We linked 4 mpox cases in South Ubangi, Democratic Republic of the Congo, to transboundary transmission from Central African Republic. Viral genome sequencing demonstrated that the monkeypox virus sequences belonged to distinct clusters of subclade Ia. This finding demonstrates the borderless nature of mpox and highlights the need for vigilant regional surveillance.
Mpox is a zoonotic viral infectious disease first identified in humans in the Democratic Republic of the Congo (DRC) in 1970 (1). Monkeypox virus (MPXV) is endemic to forested regions of Central and West Africa (2) and is subclassified into clade I and clade II; subclade IIb was responsible for a global epidemic in 2022 (3). We have recommended subdivision of clade I into subclades Ia and Ib, where subclade Ib is associated with sustained human-to-human transmission in the DRC (4). Clade I is endemic to Central Africa, particularly in the DRC, and infections are associated with greater disease severity than for clade II infection (5,6). Zoonotic spillover has been the primary driver of clade I MPXV infections; however, sustained human-to-human transmission is increasing, and spread of clade I MPXV through sexual contact has been reported in multiple regions of the DRC (4,7).
Among mpox-endemic regions, the DRC has been the most severely affected. The number of reported cases has increased since the cessation of smallpox vaccination campaigns in 1980 (8). This increase accelerated from 2022 onwards (9), including into regions with no previously reported cases (10). Cross-border travel has been demonstrated as a factor in transmission of clade II MPXV, but less is known for clade I cases in regional settings. Given the recent geographic expansion for clade I MPXV and increasing observation of sustained human-to-human transmission, considerable concerns exist about geographic expansion of mpox through cross-border transmission (10).
The Central African Republic (CAR) shares a >1,000-mile border with the DRC. CAR has reported 40 confirmed mpox outbreaks (95 suspected cases during 2001–2021), increasing from 0–2 annually during 2001–2017 to 9 annually since 2018 (11). Most of those outbreaks occurred in 2 regions along the border with the DRC. Here, we report suspected cross-border transmission of mpox between CAR and the DRC in 2023 and potential links to MPXV circulation in DRC.
The South Ubangi Provincial Health Division in the DRC issued an alert for a suspected mpox case in January 2023 after the death of a fisherman displaying respiratory distress and skin lesions in Mbaya Health Zone. South Ubangi directly borders CAR, separated by the Ubangi River. The National Programme for Control of Mpox and Viral Hemorrhagic Fevers and the National Institute for Biomedical Research deployed a multidisciplinary team to investigate the case with the Provincial Health Division. As part of the investigation, the national and provincial health teams conducted supplemental training sessions to raise awareness of the clinical signs and transmission modes for mpox.
The index case was an adult man residing in Bangui, CAR, who moved frequently between CAR and the DRC by the Ubangi River (cluster 1, case 1: C1) (Figure 1). After suspected exposure to wildlife meat and the potential consumption of rodents in CAR in early January 2023, symptom onset began shortly after (day 0); symptoms were fever, headache, chills, and cutaneous rash. After traveling to the DRC, he was admitted to Mbaya General Reference Hospital 2 days later, where he died on day 9 after symptom onset, after experiencing respiratory distress. No samples or information on his immune status were collected from this probable mpox case-patient.
We identified 15 contacts of the patient in Mbaya Health Zone, consisting of 5 healthcare workers and 10 close contacts (4 close friends and 6 family contacts). The investigation revealed a cluster of 3 symptomatic family contacts. Of those, 2 contacts had samples taken, and both tested positive for MPXV by PCR; those contacts were the adult female partner of C1 (C2) and their child (C3). A second child of C1 and C2 (C4) was treated locally for suspected mpox using traditional methods and was not investigated further. No suspected mpox cases were identified among family or close contacts of C1 in Bangui.
During the investigation, we identified a distinct second mpox cluster, which likely originated from a different source. We identified 3 suspected mpox cases in the same hospital at the same time as the first cluster that had no known epidemiologic link. An adult woman (cluster 2, case 1: D1) was hospitalized for nonspecific signs of mpox at the same time as C1 and reported contact with a child with mpox symptoms ≈28 days before. The 2 additional suspected cases were the child of D1 (D2), in whom mpox was subsequently confirmed by PCR, and a contact of D2 (D3), who tested negative by PCR (Figure 2). Confirmed mpox clinical symptoms included multiple pustular and papular lesions (C2); disseminated pustules (C3); discreet lacrimation in the left eye and postinflammatory hyperpigmentation (D1); and hyperpigmented, disseminated macules and steep-edged ulcerations (D2) (Figure 3).
We subsequently performed viral genome sequencing on 3 PCR-positive samples: 2 from the first mpox cluster (C2 and C3) and 1 from the second cluster (D2) (Figure 4). Phylogenetic analysis included 98 clade I MPXV previously published genomes. We generated the phylogenetic tree by maximum-likelihood using the Kimura 3-parameter model with unequal base frequencies plus gamma distribution plus invariable sites (12,13). The 3 sequences, all clade Ia, clustered with MPXV genome sequences isolated from CAR. The genetic distance between the new cases and the date between the CAR and DRC samples is too long to conclude direct links between the 2 countries. Nevertheless, the new samples from South-Ubangi clustered in the same subgroup (group II) according to previous classification of MPXV sequences in clade Ia (14).
Further, the National Programme for Control of Mpox and Viral Hemorrhagic Fevers investigated 109 suspected mpox cases from 15 health zones in South Ubangi during January–November 2023. Case-patients were predominantly male (60 male and 46 female; data were unavailable for 3 cases); the average age was 21 years (range 35 months–63 years). Of those, 61 cases (56%) were confirmed positive by PCR at National Institute for Biomedical Research. Three of the 46 mpox-negative cases (6%) were confirmed as positive for varicella zoster virus.
This investigation describes 2 distinct clusters of mpox cases in Mbaya Health Zone in South Ubangi Province in the DRC, presumably resulting from 2 different introductions. We identified epidemiologic links to cross-border travel from CAR for the first cluster and identified genomic links with historic CAR cases for both clusters. MPXV transmission in the DRC is currently driven by both zoonotic and human-to-human contact, thus increasing the complexity of containment and mitigation efforts. Wider regional and international expansion of mpox, specifically, the concentration of MPXV outbreaks in CAR and the DRC along the Ubangi River, recent sustained human-to-human transmission, resource limitations for identifying and treating mpox, disease stigma, population displacement because of conflict, and transient cross-border transit are serious concerns.
In August 2022, a first regional meeting involving 6 neighboring countries of Central and West Africa was held in Kinshasa, the DRC, to establish a regional mpox surveillance network, the Mpox Threat Reduction Network. Through this network, multiple teams including experts from the Health Ministries of the DRC and CAR were able to communicate rapidly on suspected cases crossing borders in South Ubangi while also reporting to International Health Regulations focal points. Considering the relatively porous borders in the Central African region and continuing increases in reported mpox cases, documenting transboundary mpox transmission is critical. This investigation highlights the importance of long-term collaborative partnerships for sustained mpox surveillance and containment in endemic regions.
Dr. Vakaniaki is a medical researcher and ecoepidemiologist at the Institut National de Recherche Biomédicale and a predoctoral fellow at the Antwerp Institute of Tropical Medicine. His research focuses on emerging and re-emerging infectious diseases, the contribution of vaccination to the control of vaccine-preventable diseases, and health risks in the context of One Health.
This article was published as a preprint at https://www.medrxiv.org/content/10.1101/2024.08.13.24311555v1.
Acknowledgments
We thank Gradi Luakanda for his continued support of this work. All maps were generated using qGIS version 3.30. All efforts presented in this work are part of regular public health surveillance conducted by the Ministry of Health and partners in the DRC and CAR.
The project or effort depicted is sponsored by the Department of Defense Threat Reduction Agency and United States Department for Agriculture (USDA) Agriculture Research Service (ARS). The content of the information does not necessarily reflect the position or the policy of the US federal government, and no official endorsement should be inferred. This work was also supported by the International Mpox Research Consortium (IMReC) through funding from the Canadian Institutes of Health Research and International Development Research Centre (Grant No. 202209MRR-489062-MPX-CDAA-168421) and the Agence Française de Développement through the PANAFPOX and AFROSCREEN project (grant agreement CZZ3209), coordinated by ANRS Maladies infectieuses émergentes in partnership with Institut de Recherche pour le Développement (IRD). E.L. received a PhD grant from the French Foreign Office.
References
- Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46:593–7.PubMedGoogle Scholar
- Titanji BK, Tegomoh B, Nematollahi S, Konomos M, Kulkarni PA. Monkeypox: a contemporary review for healthcare professionals. Open Forum Infect Dis. 2022;9:
ofac310 . DOIPubMedGoogle Scholar - Happi C, Adetifa I, Mbala P, Njouom R, Nakoune E, Happi A, et al. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biol. 2022;20:
e3001769 . DOIPubMedGoogle Scholar - Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O’Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. 2024. DOIPubMedGoogle Scholar
- Weaver JR, Isaacs SN. Monkeypox virus and insights into its immunomodulatory proteins. Immunol Rev. 2008;225:96–113. DOIPubMedGoogle Scholar
- Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, Kalonji-Mukendi T, Pukuta E, Hoff NA, et al.; International Mpox Research Consortium. Clade I–associated mpox cases associated with sexual contact, the Democratic Republic of the Congo. Emerg Infect Dis. 2024;30:172–6. DOIPubMedGoogle Scholar
- Ministry of Public Health, Hygiene and Prevention of the Democratic Republic of the Congo. Report on the epidemiological situation of monkeypox virus—S1–S6 2024. Kinshasa: The Ministry; 2024.
- World Health Organization. Disease Outbreak News: mpox—Democratic Republic of the Congo; 2024 Jun 14 [cited 2024 Jun 25]. https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON522
- Mbala-Kingebeni P, Rimoin AW, Kacita C, Liesenborghs L, Nachega JB, Kindrachuk J. The time is now (again) for mpox containment and elimination in Democratic Republic of the Congo. PLOS Glob Public Health. 2024;4:
e0003171 . DOIPubMedGoogle Scholar - Besombes C, Mbrenga F, Schaeffer L, Malaka C, Gonofio E, Landier J, et al. National monkeypox surveillance, Central African Republic, 2001–2021. Emerg Infect Dis. 2022;28:2435–45. DOIPubMedGoogle Scholar
- Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017;14:587–9. DOIPubMedGoogle Scholar
- Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37:1530–4. DOIPubMedGoogle Scholar
- Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon B, et al. Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018. Sci Rep. 2021;11:13085. DOIPubMedGoogle Scholar
Figures
Suggested citation for this article: Vakaniaki EH, Kinganda-Lusamaki E, Merritt S, Kasongo F, Malembi E, Lunyanga L, et al. Presumed transmission of 2 distinct monkeypox virus variants from Central African Republic to Democratic Republic of the Congo. Emerg Infect Dis. 2024 Oct [date cited]. https://doi.org/10.3201/eid3010.241118
Original Publication Date: August 29, 2024
1These authors equally cosupervised this work.
Table of Contents – Volume 30, Number 10—October 2024
EID Search Options |
---|
|
|
|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Anne W. Rimoin, Department of Epidemiology, Gordon-Levin Endowed Chair in Infectious Diseases and Public Health, UCLA Fielding School of Public Health, 650 Charles E. Young Dr, CHS 41-275, Los Angeles, CA 90095, USA
Top